HRTIS Stock Overview
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Herantis Pharma Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.43 |
| 52 Week High | €2.20 |
| 52 Week Low | €1.17 |
| Beta | 0.31 |
| 1 Month Change | 1.06% |
| 3 Month Change | -2.39% |
| 1 Year Change | -31.90% |
| 3 Year Change | -45.42% |
| 5 Year Change | -73.52% |
| Change since IPO | -86.50% |
Recent News & Updates
Shareholder Returns
| HRTIS | FI Pharmaceuticals | FI Market | |
|---|---|---|---|
| 7D | -0.3% | 3.4% | -0.8% |
| 1Y | -31.9% | 8.2% | -15.7% |
Return vs Industry: HRTIS underperformed the Finnish Pharmaceuticals industry which returned 8.2% over the past year.
Return vs Market: HRTIS underperformed the Finnish Market which returned -15.7% over the past year.
Price Volatility
| HRTIS volatility | |
|---|---|
| HRTIS Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FI Market | 7.7% |
| 10% least volatile stocks in FI Market | 3.2% |
Stable Share Price: HRTIS has not had significant price volatility in the past 3 months.
Volatility Over Time: HRTIS's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Finnish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 10 | Antti Vuolanto | herantis.com |
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.
Herantis Pharma Oyj Fundamentals Summary
| HRTIS fundamental statistics | |
|---|---|
| Market cap | €28.83m |
| Earnings (TTM) | €279.84k |
| Revenue (TTM) | n/a |
103.0x
P/E Ratio0.0x
P/S RatioIs HRTIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRTIS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | -€279.84k |
| Earnings | €279.84k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 0.014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.7% |
How did HRTIS perform over the long term?
See historical performance and comparison